
[Federal Register: April 27, 2010 (Volume 75, Number 80)]
[Notices]               
[Page 22147-22148]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27ap10-71]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0001]

 
Tobacco Product Constituents Subcommittee of the Tobacco Products 
Scientific Advisory Committee; Notice of Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Tobacco Product Constituents Subcommittee of the 
Tobacco Products Scientific Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on June 8, 2010, from 8:30 
a.m. to 5 p.m. and on June 9, 2010, from 8 a.m. to 5 p.m.
    Location: Holiday Inn, The Ballrooms, 2 Montgomery Village Ave., 
Gaithersburg, MD 20879. The hotel phone number is 301-948-8900.
    Contact Person: Karen Templeton-Somers, Office of Science, Center 
for Tobacco Products, Food and Drug Administration, 9200 Corporate 
Blvd., Rockville, MD 20850, 1-877-287-1373 (choose Option 4), e-mail: 
TPSAC@fda.hhs.gov or FDA Advisory Committee Information Line, 1-800-
741-8138 (301-443-0572 in the Washington, DC area), code 8732110002. 
Please call the Information

[[Page 22148]]

Line for up-to-date information on this meeting. A notice in the 
Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the agency's Web site and call the appropriate 
advisory committee hot line/phone line to learn about possible 
modifications before coming to the meeting.
    Agenda: On June 8 and 9, 2010, the subcommittee will receive 
presentations and discuss the development of a list of harmful or 
potentially harmful constituents, including smoke constituents, in 
tobacco products. Topics for discussion will include the criteria for 
selection of the constituents, developing a proposed list of harmful or 
potentially harmful constituents, the rationale for including each 
constituent, and the acceptable analytical methods for assessing the 
quantity of each constituent. A second meeting of this subcommittee, to 
continue these discussions as necessary and to include ancillary and 
normalization standards for the constituents, will be scheduled for the 
summer of 2010.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate advisory committee link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before May 
28, 2010. Oral presentations from the public will be scheduled between 
approximately 2:45 p.m. and 3:45 p.m. on June 8, 2010. Those desiring 
to make formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before May 20, 2010. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by May 21, 2010.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Karen Templeton-
Somers at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/
AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 21, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-9662 Filed 4-26-10; 8:45 am]
BILLING CODE 4160-01-S

